Cytotoxic T lymphocytes (CTLs) may play a role in host defence against hepatitis C virus (HCV) infection, and HCV-specific CTL epitopes may be included in vaccines to induce protective CTLs. We identified three new epitopes within the HCV nucleoprotein recognized by CTLs. HCV nucleoprotein residues 28-37 are the minimal epitope recognized by CTLs in association with the class I human leukocyte antigen B60, and epitopes in HCV nucleoprotein residues 111-130 and 161-180 are both recognized by CTLs in association with the class II human leukocyte antigen DRB 1"08032.
Hepatitis C virus (HCV) infection frequently persists and results in chronic hepatitis, cirrhosis, and, eventually, hepatocellular carcinoma. Although post-transfusion acute hepatitis C has substantially decreased since the introduction of an anti-HCV assay for blood screening, sporadic acute hepatitis C still occurs. Interferon therapy is effective for less than 50 % of patients with chronic hepatitis C. HCV has been reported to escape recognition by neutralizing antibodies by mutating amino acids in a potential antigenic region within an HCV envelope protein (Shimizu et al., 1994) . Thus, it is necessary to develop new strategies to prevent and treat HCV infection.
Cytotoxic T lymphocytes (CTLs) are thought to be a major host defence against viral infection and have also been implicated in the immunopathogenesis of viral infection. HCV-specific CTLs are present in both the peripheral blood (Kita et al., 1993) and among lymphocytes infiltrating the liver (Koziel et al., 1992) in patients with chronic hepatitis C.
Since CTLs restricted by distinct human leukocyte antigens (HLAs) recognize different epitopes, a universally immunogenic HCV CTL vaccine would require multiple epitopes. Epitopes in HCV antigens recognized by CTLs cultured from peripheral blood lymphocytes (PBLs) or lymphocytes infiltrating the liver of patients * Author for correspondence. Fax + 81 285 40 6054. e-mail imawari@ari.bekkoame.or.jp with HCV infection have been identified in association with HLA B44 (Kita et al., 1993 (Kita et al., , 1995 , B35, A29 (Koziel et al., 1992) , B50, A11, B7, B51 (Koziel et al., 1993) , B53, A23, A3, B8 (Koziel et al., 1995) and A2 (Shirai et al., 1994; Battegay et al., 1995; Cerny et al., 1995; Koziel et al., 1995) . In the present study, we describe three new epitopes within the HCV nucleoprotein that are recognized by CTLs.
Two patients with biopsy-proven chronic hepatitis C were studied. Both patients were infected with HCV of genotype lb/II according to the classifications of P. Simmonds and colleagues (Chan et al., 1992) and H. Okamoto (Okamoto et al., 1992) . Patient 1 had fluctuating serum concentrations of alanine aminotransferase (ALT); the patient's HLA haplotype was A2, A31, B35, B60, Cw3, DRBl*08032/1502, DQBI*0601/ 0601 and DPBI*0501/0901. Patient 2 had increased concentrations of serum ALT (> 300 IU/1) during the study; this patient's HLA haplotype was A24, A33, B44, B46, Cwl, Cw3, DRBl*08032/1302, DQBl*0601/0604 and DPBI*0201/0501. Five other HLA B60-positive patients with chronic hepatitis C were also studied. reported (Kita et al., 1993) . MIX A contains five overlapping peptides, NP1 to NP5, spanning HCV nucleoprotein residues 1-60; MIX B NP6-NP10, spanning residues 51-110; MIX C NPll NP14, spanning residues 101-150; MIX D NP15-NP18, spanning residues 141-191. The amino acid sequence was deduced from a cDNA (HCV-TK; GenBank accession no. D83645) encoding 191 amino acids of the HCV nucleoprotein cloned from the serum of patient 1, and the sequence identified as HCV of genotype lb/II. A recombinant vaccinia virus (VAC-HCVc) that expresses the nucleoprotein was constructed as previously reported (Kita et al., 1993) . CTLs were cultured by repeated stimulation of PBLs with a mixture of synthetic peptides or a single peptide as reported previously (Kita et al., 1993) . PBLs were suspended at a cell density of 1 x 10 ~ cells/ml in RPMI 1640 medium supplemented with 10 % human AB serum and 10 gg of each synthetic peptide/ml. On day 2 after stimulation, Lymphocult T (Biotest Diagnostics) was added to a final concentration of 10% (10 U/ml) as a source of interleukin-2. On day 7, the culture was restimulated with the peptide and was co-cultivated with irradiated autologous PBLs (30 Gy). On days 14-16, the cytotoxic activity of peptide-stimulated effector cells was assessed with a 5 h europium (Eu)-release assay using Epstein-Barr virus-transformed B cell lines (BCLs) sensitized with peptides or infected with VAC-HCVc as targets (Kita et al., 1993) .
The phenotype of CTLs was determined by assessing the cytotoxic activity of peptide-stimulated effector cells depleted of CD4 + T cells or CD8 + T cells. CTLs were depleted of CD4 + T cells or CD8 + T cells with CD4 or CD8 monoclonal antibody-coated magnetic Dynabeads (Dynal).
When PBLs were stimulated twice with a mixture of synthetic peptides, CTLs specifically lysing peptide MIX A-pulsed, MIX C-pulsed and peptide MIX D-pulsed autologous BCLs were detected in patients 1 and 2, respectively (data not shown). Peptide MIX A-stimulated CTLs lysed NP3-pulsed autologous BCLs (Fig. l a) , indicating that the epitope was in HCV nucleoprotein residues 21-40 (DVKFPGGGQIVGGVYLLPRR). Peptide MIX C-stimulated CTLs lysed NP12-pulsed autologous BCLs (Fig. 1 b) , and peptide MIX D-stimulated CTLs lysed NP17-pulsed autologous BCLs (Fig. lc) , indicating that the epitopes were in residues 111 130 (DPRRRSRNLGKVIDTFTCGL) and 161-180 (SVNYATGNLPGCSFSIFLLA), respectively. The CTL activity of MIX A-stimulated effector cells was abrogated by depletion of CD8 + T cells but not by depletion of CD4 + T cells, while the CTL activities of MIX C-stimulated and MIX D-stimulated effector cells were abrogated by depletion of CD4 + T cells but not by depletion of CD8 + T cells (data not shown). These findings indicate that NP3-specific CTLs are CD8 + T cells and that NP12-specific and NP17-specific CTLs are CD4 + T cells.
HLA restriction of NP3, NP12 and NP17 peptide recognition was studied with a panel of autologous and PBLs of patient 1 stimulated with NP3 and PBLs of patient 2 stimulated with MIX C or MIX D were assayed for cytotoxicity to panels of autologous and allogeneic BCLs pulsed with NP3, NP12 and NP17, respectively, at an effector-to-target cell ratio of 40. Percentage specific cytotoxicity was calculated as described in the legend to Fig. 1 allogeneic BCLs with known HLA haplotypes. NP3-specific CTLs selectively lysed NP3-sensitized BCLs expressing HLA B60, while NP12-specific and NP17-specific CTLs selectively lysed NP12-sensitized BCLs and NP17-sensitized BCLs, respectively, expressing HLA DRBl*08032 (Fig. 2) . These findings indicate that NP3 * Cytotoxicity assays were performed at an effector to target cell ratio of 40. Target cells were sensitized with peptides at a concentration of 10 ~M. Percentage specific cytotoxicity was calculated as described in the legend to Fig. 1. recognition is restricted by HLA B60, while recognition of both NP12 and NP17 is restricted by HLA DRBl*08032.
NP3-stimulated CTLs recognized not only peptidesensitized targets but also recombinant vaccinia virusinfected targets that synthesize HCV nucleoprotein endogenously although lysis of recombinant vaccinia virus-infected targets was less efficient than that of peptide-pulsed targets (data not shown). Whether or not NP12-stimulated CTLs and NP17-stimulated CTLs recognize endogenously synthesized antigens remains unclear since CTLs were detectable in the peripheral blood of patient 2 for only 6 months, and recombinant vaccinia virus was not available during that period. The reason why we could detect the CTL responses for only 6 months remained unknown.
The fine specificity of the HLA B60-restricted CTLs was assessed with panels of truncated and overlapping peptides. Cytotoxic activity was observed exclusively against peptides containing a 9-mer peptide consisting of HCV nucleoprotein residues 28-36, GQIVGGVYL (Table 1) . A recently proposed HLA B60-binding peptide motif has a negatively charged glutamic acid residue at position 2, a hydrophobic amino acid residue, such as isoleucine or valine, at position 7, and a leucine residue at the carboxyl terminus (Falk et al., 1995) . However, the minimal epitope for HLA B60-restricted CTLs specific for HCV nucleoprotein had an uncharged polar glu-tamine residue at position 2. The minimal epitopes for NP12-specific CTLs and NP17-specific CTLs could not be determined because the CTLs were detectable for only a limited period of time.
NP3-specific CTLs were examined in five additional patients with HCV infection expressing HLA B60. PBLs from two HCV-infected patients were stimulated with NP3, but CTLs were not detectable in PBLs from either. PBLs from the remaining three HCV-infected patients were stimulated with the 9-mer peptide 28-36, and CTLs were detectable in one of them (data not shown).
Patient 2 Although CTLs are generally CD8 + and HLA class Irestricted, the presence of CD4 +, HLA class II-restricted CTLs has also been reported (Jacobson et aI., 1984; Yasukawa & Zarling, 1984) . It has been suggested that CD4 + CTLs terminate the immune response to antigens rather than act as antiviral effector cells (Braakman et al., 1987) . However, it has been reported that as well as exogenous antigens, some endogenously synthesized antigens can be presented by MHC class II molecules and be recognized by CD4 + CTLs (Jacobson et al., 1989; Jaraquemada et al., 1990) . Such CTLs have been shown to be involved in the pathogenesis of viral infection and the immune clearance of infected cells, although CD4 + CTLs may be less effective for viral clearance than CD8 + CTLs (Muller et al., 1992) . Thus, NP12-stimulated CD4 + CTLs and NP17-stimulated CD4 + CTLs may play a role in the host defence against HCV infection, although whether or not these CTLs can recognize endogenously synthesized HCV nucleoprotein remains to be seen. Alternatively, CD4 + HCV nucleoprotein peptide-specific CTLs may be involved in the immunopathogenesis of viral infection rather than viral clearance as postulated for herpes simplex virus infection (Yasukawa et al., 1989) .
Recently, we observed that a detectable CTL response to the HCV nucleoprotein is associated with a decreased serum HCV RNA titre in patients with HCV infection who express HLA B44 (K. Hiroishi, H. Kita, M. Kojima, H. Okamoto, T. Moriyama, T. Kaneko, T. Ishikawa, T. Aikawa, N. Tanaka, K. Mitamura & M. Imawari, unpublished results). This finding suggests that a vaccine that induces HCV-specific CTLs may be useful for the prevention and elimination of HCV infection.
A universally immunogenic HCV CTL vaccine would require multiple epitopes, preferably from the conserved regions of HCV. The amino acid sequence of the HCV nucleoprotein between residues 28-36 is highly conserved between HCV isolates from the same group and between the different groups of HCV, while the sequences between residues 111 130 and 161-180 are conserved between isolates from the same genotype (Weiner et al., 1991) . The peptides used in the present study were synthesized based on the amino acid sequence of genotype lb/II HCV. Thus, peptide 28-36 would induce CTLs that would recognize most HCV strains irrespective of the genotype, and peptides 111-130 and 161-180 would induce CTLs that would recognize at least HCV isolates of genotype lb/II.
In conclusion, the results demonstrate that the 9-mer HCV nucleoprotein peptide 28-36 is the minimal epitope recognized by CTLs in association with HLA B60, and that peptides 111-130 and 161-180 both contain epitopes recognized by CTLs in association with HLA DRB 1"08032. These peptides may provide the basis for a vaccine to induce a sufficient anti-viral CTL response to prevent HCV persistence in persons expressing HLA B60 or HLA DRBl*08032 and to eliminate HCV from infected patients expressing HLA B60 or HLA DRBl*08032.
